## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property **Organization**

International Bureau



# T CONTRE THE LOCAL THE EXEMPLE CONTREMENT OF CONTREMENT OF CONTREMENT OF CONTREMENT OF CONTREMENT OF CONTREMENT

(43) International Publication Date 4 November 2004 (04.11.2004)

PCT

### (10) International Publication Number WO 2004/094468 A2

(51) International Patent Classification7:

(21) International Application Number:

C07K 14/315

PCT/EP2004/004429

23 April 2004 (23.04.2004)

(25) Filing Language:

English

(26) Publication Language:

(22) International Filing Date:

**English** 

(30) Priority Data:

0309246.7

23 April 2003 (23.04.2003) GB

0329112.7 16 December 2003 (16.12.2003) GB

(71) Applicant (for all designated States except US): HANSA MEDICAL RESEARCH AB [SE/SE]; Edison Park, S-223 69 Lund (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BJÖRCK, Lars [SE/SE]; Magle Stora Kyrkogata 10, S-223 50 Lund (SE). HERWALD, Heiko [DE/SE]; Kyrkogatan 8, S-24014 Veberöd (SE). MÖRGELIN, Matthias [SE/SE]; Tre Högars Väg 26B, S-224 75 Lund (SE). RUSSELL, Wayne [GB/SE]; Hallandsgatan 7, S-224 32 Kävlinge (SE). NORRBY-TEGLUND, Anna [SE/SE]; Gustavslundsvägen 19, S-144 63 Rönninge (SE). LINDBOM, Lennart [SE/SE]; Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm (SE). SOL-LENBERG, Ulla [SE/SE]; Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm (SE). CRAMER, Henning [DE/DE]; Ludwigshafener Strasse 50, 65929 Frankfurt (DE). FLODGAARD, Hans [DK/DK]; Melvillevej 6, DK-2900 Hellerup (DK).

- (74) Agents: ROQUES, Sarah, Elizabeth et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND TREATMENT

(57) Abstract: A method for identifying an anti-streptococcal agent, comprises: (a) providing, as a first component, an isolated streptococcal M protein or a functional variant thereof; (b) providing, as a second component, isolated fibrinogen or a functional variant thereof; (b) providing, as a third component, an isolated  $\beta_2$  integrin or a functional variant thereof; (d) contacting said components with a test substance under conditions that would permit the components to interact in the absence of the test substance; and (e) determining whether the test substance inhibits the interaction between the components; thereby to determine whether a test substance is an anti-streptococcal agent.

